Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC

Go back to Novocure (NVCR) Reports Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in NSCLC
(NASDAQ: NVCR) Delayed: 219.92 --0 (-0%)
Previous Close $219.92    52 Week High $28.95 
Open $219.92    52 Week Low $5.95 
Day High $219.92    P/E N/A 
Day Low $219.92    EPS $0.00 
Volume